Question 1

What is the FDA status of BPC-157 Arginate Salt (FDA Regulatory Context)?

Accepted Answer

Not approved. This record is not an FDA-approved drug product. Approval, where it exists, is specific to a drug product, indication, and route. Source: FDA primary source on file. Compounding record: Status not verified. Status not verified. Exact FDA substance context: FDA names BPC-157: Nomination withdrawn. The arginate salt is not independently verified; no inference of eligibility from salt substitution. Previously in Category 2; FDA still identifies potential significant safety risks for the named withdrawn substance. Withdrawal is not FDA approval or a determination of safety or compounding eligibility. Regulatory source checked October 10, 2026. Sources: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://www.fda.gov/media/94155/download?attachment= Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route.

Question 2

What evidence is indexed for BPC-157 Arginate Salt (FDA Regulatory Context)?

Accepted Answer

BPC-157 Arginate Salt (FDA Regulatory Context) in the literature

BPC-157 arginate salt is structurally identical to PDA (Pentadeca Arginate) — the same 15-amino-acid BPC-157 sequence bound to L-arginine as a counter-ion rather than acetate, using the same angiogeni

What the literature studies

Recovery Research

Evidence tier

Animal Only

Compounding record

Status not verified

Confidence

2/5

Question 3

Does PeptideX tell me how to use BPC-157 Arginate Salt (FDA Regulatory Context)?

Accepted Answer

No. PeptideX does not give doses, titration, cycles, stacks, reconstitution, injection technique, or where to buy.  Talk with a licensed clinician about any medicine.

BPC-157 Arginate Salt (FDA Regulatory Context)

BPC-157 Arginate Salt (FDA Regulatory Context) in the literature

Regulatory record

Questions